Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022010271 - FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF

Publication Number WO/2022/010271
Publication Date 13.01.2022
International Application No. PCT/KR2021/008681
International Filing Date 07.07.2021
IPC
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 27/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
Applicants
  • 주식회사 카나프테라퓨틱스 KANAPH THERAPEUTICS INC. [KR]/[KR]
Inventors
  • 정으뜸 CHUNG, Eu Ddeum
  • 유수민 RYU, Soomin
  • 김동건 KIM, Donggeon
  • 장지훈 CHANG, Jihoon
  • 이병철 LEE, Byoung Chul
Agents
  • 류종우 RYU, Jong Woo
  • 이내영 LEE, Rae Young
  • 한윤호 HAN, Yun Ho
Priority Data
10-2020-008353607.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF
(FR) PROTÉINES DE FUSION COMPRENANT UN INHIBITEUR DE LA VOIE DU COMPLÉMENT ET UN INHIBITEUR DE L'ANGIOGENÈSE, ET LEUR UTILISATION
(KO) 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
Abstract
(EN) Provided is a fusion protein dimer comprising a protein which specifically binds to the extracellular domain of CRIg or a fragment thereof and VEGF. The protein may inhibit complement-related pathways and also may efficiently regulate angiogenesis. Thus, the fusion protein dimer can be effectively applied to the treatment and prevention of complement-related diseases, in particular, eye diseases such as macular degeneration, and thus, has high industrial applicability.
(FR) L'invention concerne un dimère de protéine de fusion comprenant une protéine qui se lie spécifiquement au domaine extracellulaire de CRIg ou d'un fragment de celui-ci et à VEGF. La protéine peut inhiber les voies liées au complément et peut également réguler efficacement l'angiogenèse. Ainsi, le dimère de protéine de fusion peut être efficacement appliqué au traitement et à la prévention de maladies liées au complément, en particulier, des maladies oculaires comme la dégénérescence maculaire, et présente ainsi une applicabilité industrielle élevée.
(KO) CRIg의 세포외도메인 또는 이의 단편 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 이량체를 제공한다. 상기 단백질은 보체 관련 경로를 억제할 뿐 아니라 신생혈관생성을 효율적으로 조절할 수 있다. 따라서, 상기 융합단백질 이량체는 보체 관련 질환, 구체적으로 황반 변성과 같은 안질환의 치료 및 예방에 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다.
Latest bibliographic data on file with the International Bureau